Spectral AI, Inc. (NASDAQ: MDAI) shares are currently exhibiting an upward trajectory this morning, marking a gain of 9.59% and reaching $2.97 as of the last check during the current session. This surge in Spectral AI stock follows the submission of a regulatory certification application in the United Kingdom by MDAI’s subsidiary.
Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI (MDAI), has officially disclosed the submission of an application in the United Kingdom seeking registration of its advanced predictive software, DeepView AI-Burn, under the UK Conformity Assessed (UKCA) scheme for burn wound applications.
This significant step signifies a crucial milestone in the potential commercialization of the DeepView AI-Burn algorithm, representing MDAI’s inaugural AI software release designed for the evaluation and management of thermal burn wounds. The anticipated feedback on this application is expected in the first half of 2024.
Notably, the current market lacks a diagnostic tool specifically tailored for burn wounds, and early, reliable assessment of burn severity plays a pivotal role in enhancing the care of burn patients. DeepView AI-Burn, the predictive software in question, seamlessly integrates with the UKCA-approved application for the imaging device, DeepViewSnapShot.
The DeepView System efficiently processes images, presenting the original wound while accentuating non-healing sections of the burn, characterized as deep 2nd and 3rd degree burns. This diagnostic predictive analysis is swiftly delivered within seconds, providing valuable assistance to physicians in formulating well-informed decisions regarding patient treatment protocols.
The UKCA marking represents a product certification system instituted by the UK government to ensure that products available in the UK market adhere to applicable laws and technical standards. DeepView AI-Burn’s indication is specifically for individuals aged eighteen years and older.
The Company is actively exploring avenues to extend its technological offerings to cater to pediatric populations and is concurrently initiating case studies and case series in collaboration with surgeons at prominent burn centers.
